Medical Letter on the CDC & FDA
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Medical Letter on the CDC & FDA
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Thrombocytopenia Prevention
Findings from M.J. Hursting and co-authors provide new insights into thrombocytopenia prevention
June 21st, 2009
Fresh data on thrombocytopenia are presented in the report 'Reducing harm associated with anticoagulation: practical considerations of argatroban therapy in heparin-induced thrombocytopenia.' "Argatroban is a hepatically metabolized, direct thrombin inhibitor used for prophylaxis or treatment of thrombosis in heparin-induced thrombocytopenia (HIT) and for patients with or at risk of HIT undergoing percutaneous coronary intervention (PCI). The objective of this review is to summarize practical considerations of argatroban therapy in HIT," investigators in the United States report. "The US FDA-recommended argatroban dose in HIT is 2 microg/kg/min (reduced in patients with...
Source: Medical Letter on the CDC & FDA (2009-06-21)
|
